In a new research paper, 69É«ÇéƬ experts examine and measure the benefit of using medical claims data in addition to prescription data through the Irix Rules and Risk Score to improve underwriting decisions.
Explore the details by downloading this free report.
What do we gain in underwriting by accessing medical claims data (Dx) in addition to pharmacy prescriptions (Rx)?
In a new research paper, 69É«ÇéƬ experts Guizhou Hu, Laiping Wong-Stewart, Jacqueline Waas, and Taylor Pickett examine the Milliman Intelliscript Medical Data product, as well as the Milliman Irix Rules Engine and the Irix Risk Score for mortality.
The study sought to evaluate and gain a better understanding of the incremental value medical claims have in addition to prescription data.
What was that value and benefit of adding Dx to Rx from the Irix Rules perspective? Where were the most significant increases and decreases in declines? Did the top reasons for decline remain the same? Above all, does adding to Dx to Rx lead to better underwriting decisions and, if so, how?
Find out all the details in this in-depth, comprehensive report.
